Scynexis (SCYX) Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospit

SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital

Consistent with prior two interim analyses, FURI results confirm positive clinical activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal infections, including those caused by resistant strains1st Interim analysis of CARES study shows strong clinical activity of oral ibrexafungerp in patients with Candida auris, a high-mortality infection classified by CDC as an Urgent Threat to public healthResults support continued enrollment in both studies, with potential future submissions under the LPAD regulatory pathwayConference call to be held March 2nd, 2021... More